Second Military Medical University
36
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 36 trials
100.0%
+13.5% vs industry average
19%
7 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (36)
Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding
Role: collaborator
Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection (POSTCA)
Role: collaborator
Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Role: collaborator
Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery
Role: lead
The Composite Steep-pulse Treatment Apparatus Used in Prostate Cancer Ablation Therapy
Role: lead
Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma
Role: collaborator
A Study of a New Local Anesthesia Method for Transperineal Prostate Biopsy
Role: lead
The Efficacy and Safety of Composite Steep-pulse Treatment Apparatus Used in Prostate Cancer Focal Therapy
Role: lead
Nutrition and Lifestyle Study Cohort of Colorectal Cancer in China
Role: collaborator
Nutrition and Lifestyle Study Cohort of Gastric Cancer in China
Role: collaborator
Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
Role: collaborator
Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Role: collaborator
Laparoscopic Surgery VS RFA for Recurrent HCC
Role: collaborator
Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma
Role: lead
Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia
Role: lead
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
Role: lead
Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis
Role: lead
Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract
Role: lead
Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma
Role: lead
Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer
Role: lead